Abstract Body

Background:

Lenacapavir (LEN) is a potent HIV-1 capsid inhibitor (Gilead Sciences) currently in phase 2/3 clinical trials. Structural studies indicate that LEN binds two neighboring capsid subunits and stabilizes the cone-shaped capsid lattice, but its mechanism of viral inhibition and effect on capsids remain elusive. We recently utilized two different capsid-labeling approaches and demonstrated that intact HIV-1 capsids enter the nucleus and retain their integrity until just minutes before capsid disassembly (uncoating). Here, we sought to determine the effects of LEN on viral core integrity and kinetics of uncoating using isolated viral cores and cell-based assays.

Methods:

We used two capsid-labeling

Methods:

green fluorescent protein (GFP) fused to capsid (GFP-CA) and GFP as a fluid phase content marker (iGFP) by inserting GFP between matrix and capsid (GagiGFP) that was proteolytically cleaved from Gag during virion maturation. Some of the GFP remains trapped inside capsids and serves as a reporter of capsid integrity loss. HIV-1 viral cores isolated through sucrose gradient fractionation were characterized by immunostaining and single virion analysis (SVA). SVA and live-cell imaging were then used to investigate the effects of LEN on isolated capsids and nuclear capsids in infected HeLa cells, respectively.

Results:

Immunostaining showed that only capsids labeled with GFP-CA, not iGFP, were stained with anti-GFP antibody. In addition, GFP-CA, but not iGFP, inhibited Mx2 restriction of HIV-1 infection, indicating that GFP-CA is incorporated into the capsid lattice and exposed on the outside. The number of GFP-CA-labeled capsids either increased or remained constant upon LEN treatment, while the number of iGFP-labeled capsids was significantly reduced in a dose-dependent manner. Live-cell imaging showed that upon LEN treatment, GFP-CA-labeled nuclear capsids remained detectable for >1 hour, while iGFP-labeled nuclear capsids disappeared within 5 minutes.

Conclusions:

Our results show that GFP-CA is an HIV-1 capsid lattice marker and iGFP is a reporter of core integrity. LEN treatment stabilizes the capsid lattice while disrupting core integrity. These results highlight the importance of retaining an intact capsid until shortly before integration. The high potency of LEN inhibition of HIV-1 replication may be explained in part by the disruption of core integrity, rather than inhibition of capsid disassembly.